ライフサイエンスコーパス: beta-adrenergic receptor

1 antagonist-GPCR complex of iodopindolol and beta-adrenergic receptor.

2 A-mediated phosphorylation downstream of the beta-adrenergic receptor.

3 nt-binding protein pathway downstream of the beta-adrenergic receptors.

4 e of catecholamines and activation of muscle beta-adrenergic receptors.

5 o binding of agonists to the prostacyclin or beta-adrenergic receptors.

6 al tone and for their linkage to vasodilator beta-adrenergic receptors.

7 ents in genetically manipulated mice lacking beta-adrenergic receptors.

8 ramatically enhanced by acute stimulation of beta-adrenergic receptors.

9 rmacological inhibition of muscarinic and/or beta-adrenergic receptors.

10 e Ras, and is induced upon the activation of beta-adrenergic receptors.

11 coupled receptor desensitization, especially beta-adrenergic receptors.

12 eceptors, whereas activation was mediated by beta-adrenergic receptors.

13 trosylation after agonist stimulation of the beta-adrenergic receptor, a prototypical GPCR, dissociat

14 phenotype had elevated serum titers of anti-beta-adrenergic receptor Abs, as well as increased prote

15 Here we show that beta-adrenergic receptors activate eight Galphas mutant

16 to confer this cytoprotective consequence of beta adrenergic receptor activation in this cell model.

17 beta-Adrenergic receptor activation and subsequent persi

18 We also show that beta-adrenergic receptor activation by catecholamine of

19 act heart protects against cardiotoxicity of beta-adrenergic receptor activation by isoproterenol (IS

20 beta-Adrenergic receptor activation increases the Ca(2)(

21 In the failing heart, persistent beta-adrenergic receptor activation is thought to induce

22 mulated by angiotensin II, but not following beta-adrenergic receptor activation.

23 unction of the intact heart independently of beta-adrenergic receptor activation.

24 ough voltage-dependent calcium channels upon beta-adrenergic receptor activation.

25 ferator-activated receptor gamma (PPARG) and beta-adrenergic receptor (ADRB3) genes have been linked

26 n/Hsp27 complex in response to the selective beta adrenergic receptor agonist isoproterenol, was subs

27 Administration of L-arginine and a beta-adrenergic receptor agonist (CL316, 243, respective

28 following intra-LS injections of either the beta-adrenergic receptor agonist isoproterenol (10 mug o

29 er administration of either the nonselective beta-adrenergic receptor agonist isoproterenol or the be

30 during periodic pacing in the presence of a beta-adrenergic receptor agonist isoproterenol, was sign

31 ibited enhanced inotropic sensitivity to the beta-adrenergic receptor agonist isoproterenol, with imp

32 following administration of isoproterenol, a beta-adrenergic receptor agonist known to induce cardiac

33 reated some cells with Compound 49b, a novel beta-adrenergic receptor agonist we have reported previo

34 ulation can be triggered by isoproterenol (a beta-adrenergic receptor agonist) treatment.

35 es were incubated with forskolin or with the beta-adrenergic receptor agonist, isoproterenol, to stim

36 g treatment with 50 nM Compound 49b, a novel beta-adrenergic receptor agonist.

37 ve agonist, or isoprenaline, a non-selective beta-adrenergic receptor agonist.

38 beta-Adrenergic receptor agonists had limited effects on

39 These studies demonstrate that beta-adrenergic receptor agonists in vitro can restore t

40 was threefold greater than that elicited by beta-adrenergic receptor agonists.

41 also sensitizes the channel to activation by beta-adrenergic receptor agonists.

42 ort recent evidence indicating that blocking beta-adrenergic receptors alone shortly after trauma may

43 In heart failure, common genetic variants of beta-adrenergic receptors, alpha-adrenergic receptors, a

44 to signal transduction networks that include beta-adrenergic receptors, alpha-amino-3-hydroxyl-5-meth

45 ssess the expression of alpha-1, alpha-2 and beta adrenergic receptors (alpha1-AR, alpha2-AR and beta

46 nd in most mammalian cells, the mechanism of beta- adrenergic receptor and AC compartmentalization ma

47 inephrine, a catecholamine that binds to the beta-adrenergic receptor and activates the cAMP-PKA-depe

48 beta-Adrenergic receptor and inotropic response were dec

49 We investigated beta-adrenergic receptor and muscarinic receptor regulat

50 l activity and mediates up-regulation by the beta-adrenergic receptor and PKA bound to A-kinase ancho

51 lamine biosynthesis and release, stimulating beta-adrenergic receptors and activating cAMP signaling

52 rdiac contractile signaling/function through beta-adrenergic receptors and metabolism through the ins

53 It is known that beta-adrenergic receptors and NA can boost LTP maintenan

54 ential value of biased ligands targeting the beta-adrenergic receptors and nicotinic acid receptor GP

55 indicate that both proteins are regulated by beta-adrenergic receptors and respond antagonistically.

56 ase showed no recovery, while phospholamban, beta-adrenergic receptor, and the inotropic response ful

57 beta-adrenergic receptor antagonism after experimental s

58 Overall, beta-adrenergic receptor antagonism produced a dysfuncti

59 and absence of a alpha2-agonist (clonidine), beta-adrenergic receptor antagonist (propranolol), and b

60 Here, we asked whether a beta-adrenergic receptor antagonist might interfere with

61 Intraamygdala injections of a beta-adrenergic receptor antagonist or agonist, each tim

62 ug or 30 mug) or vehicle (Experiment 1), the beta-adrenergic receptor antagonist propranolol (2 mug)

63 We find that administration of the beta-adrenergic receptor antagonist propranolol before m

64 Healthy participants were administered the beta-adrenergic receptor antagonist propranolol or a pla

65 The beta-adrenergic receptor antagonist propranolol, adminis

66 herapies is also enhanced by administering a beta-adrenergic receptor antagonist to mice housed at 22

67 e expression, but pre-exposure to timolol, a beta-adrenergic receptor antagonist, delayed this effect

68 r antagonist, or propranolol, a nonselective beta-adrenergic receptor antagonist, delivered by osmoti

69 macrophages were prevented by propranolol, a beta-adrenergic receptor antagonist.

70 For many years, beta-adrenergic receptor antagonists (beta-blockers or b

71 Pretreatment with beta-adrenergic receptor antagonists abolished differenc

72 More recently, beta-adrenergic receptor antagonists have been found to

73 hese responses can be inhibited by alpha and beta-adrenergic receptor antagonists implying a bacteria

74 Systemic application of beta-adrenergic receptor antagonists may have detrimenta

75 y was prevented with either LTCC blockers or beta-adrenergic receptor antagonists, demonstrating a pr

76 Orthosteric beta-adrenergic receptor antagonists, known as beta-bloc

77 Despite widespread usage of beta-adrenergic receptor (AR) agonists and antagonists i

78 Beta-adrenergic receptor (AR) antagonists are frequently

79 beta-Adrenergic receptor (AR) blockers provide substanti

80 ation and determine the roles of alpha1- and beta-adrenergic receptors (AR) in the loss-of-interest i

81 To determine whether beta-adrenergic receptors are involved in the modulation

82 ense noradrenergic innervation and expresses beta adrenergic receptors (ARs).

83 Agonist-triggered downregulation of beta-adrenergic receptors (ARs) constitutes vital negati

84 Retromer-associated endosomes contain beta-adrenergic receptors as well as ionotropic glutamat

85 ious work has demonstrated that a functional beta-adrenergic receptor autocrine/paracrine network exi

86 Postsynaptic function, beta-adrenergic receptor (BAR) density (B'(max)), was me

87 e glucose counterregulation via specific VMH beta-adrenergic receptors (BAR).

88 Propranolol (beta-adrenergic receptor (beta-Ad) antagonist) enhanced

89 nd vasorelaxation is enhanced in response to beta-adrenergic receptor (beta-AdR) agonists in vitro.

90 beta-Adrenergic receptor (beta-AR) activation can provok

91 cently, we and others have demonstrated that beta-adrenergic receptor (beta-AR) activation is necessa

92 ssion is markedly induced in the heart after beta-adrenergic receptor (beta-AR) activation.

93 trieval and reconsolidation are dependent on beta-adrenergic receptor (beta-AR) activation.

94 We tested whether beta-adrenergic receptor (beta-AR) agonists increased SR

95 RBC organ trapping could be prevented by the beta-adrenergic receptor (beta-AR) antagonist, propranol

96 beta-Adrenergic receptor (beta-AR) blockers administered

97 n the recycling and activation of endogenous beta-adrenergic receptor (beta-AR) in HL-1 cardiac myocy

98 Chronic beta-adrenergic receptor (beta-AR) overstimulation, a ha

99 , anti-IgG, or by specific inhibitors of the beta-adrenergic receptor (beta-AR) pathway.

100 teins and their receptor integrins influence beta-adrenergic receptor (beta-AR) responses in vitro, w

101 e, a condition associated with diminution of beta-adrenergic receptor (beta-AR) responsiveness.

102 r kinase-2 (GRK2) is a critical regulator of beta-adrenergic receptor (beta-AR) signaling and cardiac

103 We used beta-adrenergic receptor (beta-AR) signaling as a protot

104 (HF) and determined PDE2-mediated effects on beta-adrenergic receptor (beta-AR) signaling in healthy

105 beta-adrenergic receptor (beta-AR) signaling was markedl

106 While beta-adrenergic receptor (beta-AR) stimulation ensures a

107 While beta-adrenergic receptor (beta-AR) stimulation leads to

108 Intracellular Ca(2+) ([Ca(2+) ]i ) and beta-adrenergic receptor (beta-AR) stimulation modulate

109 effect of SIT on the thermogenic response to beta-adrenergic receptor (beta-AR) stimulation, an impor

110 volved in cardiac dysfunction during chronic beta-adrenergic receptor (beta-AR) stimulation.

111 known as beta blockers, which antagonize the beta-adrenergic receptor (beta-AR), are an important com

112 ulates myocardial calcium transients through beta-adrenergic receptor (beta-AR)-mediated phosphorylat

113 ore prevalent mechanism and hypothesize that beta-adrenergic receptor (beta-AR)-mediated regulation o

114 It causes pathologic desensitization of beta-adrenergic receptors (beta-AR), facilitated predomi

115 co-activation of G(q)-coupled receptors and beta-adrenergic receptors (beta-AR), leading to cardiac

116 that stimulates contractility by activating beta-adrenergic receptors (beta-AR).

117 n of sympathetic nerve fibers, expression of beta-adrenergic receptors (beta-ARs) and remodeling para

118 Activation of beta-adrenergic receptors (beta-ARs) can induce a functi

119 receptor kinase (GRK)2 to agonist-stimulated beta-adrenergic receptors (beta-ARs) in HF, leading to c

120 beta-Adrenergic receptors (beta-ARs) promote brown adipo

121 beta-adrenergic receptors (beta-ARs), prototypic G-prote

122 We have shown that beta-adrenergic receptors (beta-ARs), which are activate

123 nnels can be modulated through activation of beta-adrenergic receptors (beta-ARs), which leads to an

124 also associated with enhanced stimulation of beta-adrenergic receptors (beta-ARs).

125 Activation of the beta adrenergic receptor (betaAR) induces a tightly cont

126 We examined the effect of beta-adrenergic receptor (betaAR) activation and cAMP-el

127 action potential duration (APD), mediated by beta-adrenergic receptor (betaAR) activation, requires a

128 ermore, these responses were mimicked by the beta-adrenergic receptor (betaAR) agonist isoproterenol,

129 yclic nucleotide-gated ion channel (HCN4) by beta-adrenergic receptor (betaAR) agonist stimulation.

130 fter stimulation with isoproterenol (ISO), a beta-adrenergic receptor (betaAR) agonist.

131 not elicit responses like those produced by beta-adrenergic receptor (betaAR) agonists such as isopr

132 The success of beta-adrenergic receptor (betaAR) antagonists in heart f

133 Beta-adrenergic receptor (betaAR) blockade is a standard

134 mor necrosis factor-alpha (TNFalpha) induces beta-adrenergic receptor (betaAR) desensitization, but m

135 erload caused diastolic dysfunction, altered beta-adrenergic receptor (betaAR) function, and vascular

136 udies have demonstrated associations between beta-adrenergic receptor (betaAR) polymorphisms and left

137 se (GRK)2 is a critical regulator of cardiac beta-adrenergic receptor (betaAR) signaling and cardiac

138 rdium appears to contribute to dysfunctional beta-adrenergic receptor (betaAR) signaling and cardiac

139 pharmacological and genetic manipulation of beta-adrenergic receptor (betaAR) signaling in osteoblas

140 A (PKA) are the most widely studied steps in beta-adrenergic receptor (betaAR) signaling in the heart

141 at least in part by normalization of cardiac beta-adrenergic receptor (betaAR) signaling.

142 We found that beta-adrenergic receptor (betaAR) stimulation induces up

143 psilon that plays a critical role in maximal beta-adrenergic receptor (betaAR) stimulation of Ca2+-in

144 a pharmacogenetic study for two predominant beta-adrenergic receptor (betaAR) subtypes expressed in

145 erent lines of evidence, we propose that the beta-adrenergic receptor (betaAR), cAMP and the transcri

146 nhibits protein phosphatase 2A (PP2A) at the beta-adrenergic receptor (betaAR, a GPCR) complex alteri

147 Catecholamine stimulation of beta-adrenergic receptors (betaAR) in adipocytes activat

148 beta-Adrenergic receptors (betaAR) play an important rol

149 Beta adrenergic receptors (betaARs) are G-protein-couple

150 tores by hydrolysis of triglycerides through beta-adrenergic receptor (betaARs) and protein kinase A

151 a SUMOylation-deficient mutant of Cav-3 with beta-adrenergic receptors (betaARs) alters the expressio

152 beta-adrenergic receptors (betaARs) are critical regulat

153 beta-adrenergic receptors (betaARs) are G-protein-couple

154 In heart failure, the beta-adrenergic receptors (betaARs) become desensitized

155 Activation of beta-adrenergic receptors (betaARs) enhances both the in

156 Stimulation of beta-adrenergic receptors (betaARs) provides the most ef

157 Downregulation of beta-adrenergic receptors (betaARs) under conditions of

158 epinephrine, a neuromodulator that activates beta-adrenergic receptors (betaARs), facilitates learnin

159 cts on the heart from chronic stimulation of beta-adrenergic receptors (betaARs), members of the 7 tr

160 that norepinephrine, through its actions on beta-adrenergic receptors (betaARs), modulates aversive

161 riety of signals such as those stimulated by beta-adrenergic receptors (betaARs).

162 n to regulate immune system function through beta-adrenergic receptors (betaARs); however, their role

163 n other cardiovascular diseases treated with beta-adrenergic receptor blockade (BB).

164 beta-adrenergic receptor blockade after ACS is a measure

165 restoration of KORs in the LC together with beta-adrenergic receptor blockade did not potentiate KOR

166 unique and additive beneficial effects over beta-adrenergic receptor blockade, a current pharmacolog

167 Traditional medical therapies, such as beta-adrenergic receptor blockade, are used to slow path

168 We hypothesized that beta-adrenergic receptor blocker (beta-blocker) and angi

169 yields of optically pure triazole-containing beta-adrenergic receptor blocker analogues with potentia

170 Importantly, beta-adrenergic receptor blocker therapy has been also s

171 network in the context of heart failure and beta-adrenergic receptor blocker therapy, where multiple

172 Propranolol, a nonselective beta-adrenergic receptor blocker, was reported to protec

173 beta-Adrenergic receptor blockers (beta-blockers) are co

174 th in patients with heart failure, for which beta-adrenergic receptor blockers are a mainstay therapy

175 In contrast, beta-adrenergic receptor blockers improved cardiac funct

176 The stimulation of beta-adrenergic receptors by isoproterenol (ISO) resulte

177 se muscle contractility by activation of the beta-adrenergic receptor/cAMP-dependent protein kinase p

178 Inhibition of the beta-adrenergic receptor/cAMP/PKA axis protected against

179 Catecholamines bind to beta-adrenergic receptors, causing cAMP generation and a

180 o restored by stimulating A(2A) adenosine or beta-adrenergic receptors, consistent with G(s)-protein

181 gs offer additional mechanistic insights how beta-adrenergic receptor-controlled PKA activities enhan

182 heart, adrenergic stimulation activates the beta-adrenergic receptors coupled to the heterotrimeric

183 of the T-type Ca(2+) current is initiated by beta-adrenergic receptors, cyclic AMP and cyclic AMP-dep

184 This change was initiated by beta-adrenergic receptors, cyclic AMP and protein kinase

185 duced myocardial contractility, decreases in beta-adrenergic receptor density and increases in Galpha

186 and ryanodine receptor proteins, as well as beta-adrenergic receptor density in nonfailing, hypertro

187 isal and promoted anxiety-like behavior in a beta-adrenergic receptor-dependent manner.

188 ulated by acute treadmill exercise through a beta-adrenergic receptor-dependent mechanism.

189 ercise increases SKM D2 expression through a beta-adrenergic receptor-dependent mechanism.

190 This suggests that signaling by beta-adrenergic receptors depends on temporal pattern of

191 rlying mechanisms include down-regulation of beta-adrenergic receptors, depressed postreceptor signal

192 our analysis suggests that activation of the beta-adrenergic receptor either via canonical (Gs-couple

193 tially reflecting down-regulation of cardiac beta-adrenergic receptor function in chronic hypoxia.

194 demonstrating a proximal relationship among beta-adrenergic receptor function, Ca2+ handling, and he

195 e suggested that rafts/caveolae may regulate beta-adrenergic receptor/Galpha(s) signaling, but underl

196 In the heart, activation of beta-adrenergic receptors greatly increases the L-type C

197 Therapeutic targeting of the beta-adrenergic receptors has recently shown remarkable

198 y the activation of excitatory alpha1A - and beta- adrenergic receptors in NPY/AgRP neurons, while PO

199 Triggering of beta-adrenergic receptors in adipocytes stimulates energ

200 he release of catecholamines, which activate beta-adrenergic receptors in cardiomyocytes and lead to

201 LTD is shifted by posttraining activation of beta-adrenergic receptors in fear conditioned mice, resu

202 h muscle tone in airways and the function of beta-adrenergic receptors in lungs and heart.

203 der hyperglycemic conditions and the role of beta-adrenergic receptors in regulating these responses.

204 Sympathetic stimulation of beta-adrenergic receptors in response to cold induces pr

205 In conclusion, activation of beta-adrenergic receptors in stratum lacunosum-molecular

206 salt hydrate (Sp-cAMPS) or activation of the beta-adrenergic receptor increased the phos pho ryl a ti

207 nt of rabbits with isoproterenol to activate beta-adrenergic receptors increased phosphorylation of S

208 Activation of beta-adrenergic receptors increases channel activity via

209 ly, coactivation of these receptors with the beta-adrenergic receptors induced transient ERK signalin

210 Beta-adrenergic receptor induces cAMP/Protein kinase A (

211 iotensin II receptors blockade nor alpha and beta adrenergic receptors inhibition blunted leptin-indu

212 ong been established that stimulation of the beta-adrenergic receptor inhibits insulin-stimulated glu

213 on whether propranolol through inhibition of beta-adrenergic receptors is an appropriate therapeutic

214 inase gamma (PI3Kgamma) signaling engaged by beta-adrenergic receptors is pivotal in the regulation o

215 ng Gbetagamma using the C-terminal domain of beta-adrenergic receptor kinase (cbetaARK) resulted in c

216 beta-Adrenergic receptor kinase 1 (betaARK 1 or GRK2) me

217 and ERK1/2 activation through activation of beta-adrenergic receptor kinase 1.

218 -protein-coupled receptor kinase 3 (GRK3; or beta-adrenergic receptor kinase 2) was not only necessar

219 n an intron of the gene ADRBK2, encoding the beta-adrenergic receptor kinase 2.

220 eceptor density and increases in Galphai and beta-adrenergic receptor kinase activities attenuate the

221 s; Rab5 and Gbetagamma heterodimers; and the beta-adrenergic receptor kinase.

222 However, chronic stimulation of beta-adrenergic receptors leads to impaired cardiac func

223 Additionally, we report that beta-adrenergic receptors mediate the anxiety-like pheno

224 s greater in women than men and is, in part, beta-adrenergic receptor mediated.

225 However, beta-adrenergic receptor-mediated activation of GTP-Rac-

226 onsidered to be the predominant regulator of beta-adrenergic receptor-mediated enhancement of cardiac

227 Higher levels of GRK2 can impair beta-adrenergic receptor-mediated inotropic reserve and

228 ve beneficial effects unrelated to increased beta-adrenergic receptor-mediated signaling?

229 The finding that beta-adrenergic receptor-mediated vasodilatation minimal

230 ha) as a direct transcriptional inhibitor of beta-adrenergic receptor-mediated, cyclic AMP-dependent

231 Our data suggest that the beta-adrenergic receptors offset alpha-adrenergic vasoco

232 ccur, in part, independently from alpha- and beta-adrenergic receptor-operated signaling and are inhi

233 Upon activation of beta-adrenergic receptors, phosphorylation of CaV1.2 cha

234 Advances in cardiac beta-adrenergic receptor physiology and pharmacology hav

235 Downstream from beta-adrenergic receptors, PI3Kgamma was found to partic

236 hensive picture of the inactive state of the beta-adrenergic receptors, reconciling the crystal struc

237 ved in several important cellular processes (beta-adrenergic receptor recycling, centrosome amplifica

238 o, and treatment with propranolol to inhibit beta-adrenergic receptors reduced phosphorylation.

239 exocytosis when they bind to muscarinic and beta-adrenergic receptors, respectively.

240 ocytes, and restores the DHF-induced blunted beta-adrenergic receptor responsiveness.

241 e and epinephrine (NE/E) because stimulating beta-adrenergic receptors shortly after training can enh

242 During screening for noncanonical beta adrenergic receptor signaling pathways in human uro

243 Aging hearts exhibit impaired beta-adrenergic receptor signaling and LV dysfunction.

244 as well as amelioration of abnormal cardiac beta-adrenergic receptor signaling at 4 weeks post-MI.

245 These data reveal how baseline levels of beta-adrenergic receptor signaling can influence murine

246 bit PKA activity to test the hypothesis that beta-adrenergic receptor signaling causes cell death thr

247 eptor kinase-2 (GRK2)-mediated uncoupling of beta-adrenergic receptor signaling impairs inotropic res

248 mpartmentalization may also be important for beta-adrenergic receptor signaling in other cell types.

249 testinal metabolism via increased peripheral beta-adrenergic receptor signaling in peripheral organs,

250 a possible mechanism by which restoration of beta-adrenergic receptor signaling may protect the retin

251 These data show that differences caused by beta-adrenergic receptor signaling pathway gene polymorp

252 Full reconstitution of the beta-adrenergic receptor signaling pathway in heterologo

253 and feedback and feed-forward motifs of the beta-adrenergic receptor signaling pathway.

254 of prostate cancer, we show that endothelial beta-adrenergic receptor signaling via adrenergic nerve-

255 were assessed for alterations in calcium and beta-adrenergic receptor signaling, apoptosis, and cardi

256 e production and excessive signaling through beta-adrenergic receptor signaling, which is increased w

257 endothelin-1, renin-angiotensin, and cardiac beta-adrenergic receptor signaling, which were not inhib

258 r near key protein binding sites critical to beta-adrenergic receptor signaling.

259 Bisoprolol restored RV beta-adrenergic receptor signaling.

260 ociation with dysregulated Ca2+ handling and beta-adrenergic receptor signaling.

261 ulated in HF patients, causing dysfunctional beta-adrenergic receptor signaling.

262 ty in brown adipocytes through modulation of beta-adrenergic receptor signaling.

263 ivator Crtc3 promotes obesity by attenuating beta-adrenergic receptor signalling in adipose tissue.

264 at for the same receptor molecule (e.g., the beta-adrenergic receptor), some agonists have a propensi

265 ce of AC6 was associated with a 48% decay in beta-adrenergic receptor-stimulated cAMP production in c

266 ements of cell shortening revealed augmented beta-adrenergic receptor-stimulated cardiomyocyte contra

267 ) adipocytes, insulin was unable to suppress beta-adrenergic receptor-stimulated glycerol release.

268 Chronic ethanol feeding suppressed beta-adrenergic receptor-stimulated lipolysis in both in

269 sing aortic constriction combined with daily beta-adrenergic receptor stimulation (ACi) and show that

270 tion potential duration, supersensitivity to beta-adrenergic receptor stimulation and Ca(2+) mishandl

271 egulation in mouse hearts undergoing chronic beta-adrenergic receptor stimulation and in a rat model

272 timulated Ca(2)(+) current in the absence of beta-adrenergic receptor stimulation and in voltage-depe

273 ate and attenuate the deleterious effects of beta-adrenergic receptor stimulation in septic shock.

274 se previous experimental studies showed that beta-adrenergic receptor stimulation increases the rate

275 , as the regulation of beating rate by local beta-adrenergic receptor stimulation of the sinoatrial n

276 ospholamban, a process that does not require beta-adrenergic receptor stimulation or protein kinase A

277 st experimental demonstration that localized beta-adrenergic receptor stimulation produces spatiotemp

278 sults in spontaneous SR Ca(2+) releases upon beta-adrenergic receptor stimulation with isoproterenol

279 Local beta-adrenergic receptor stimulation with noradrenaline

280 in phospholamban phosphorylation produced by beta-adrenergic receptor stimulation, phosphodiesterase

281 epolarization phenotype, particularly during beta-adrenergic receptor stimulation, remain unclear.

282 els the changes observed experimentally with beta-adrenergic receptor stimulation.

283 associated with excess Ca2+ influx and acute beta-adrenergic receptor stimulation.

284 d secretion of alpha-amylase secretion after beta-adrenergic receptor stimulation.

285 CaR potency as well as selectivity over the beta-adrenergic receptor subtypes.

286 ogression in part owing to uncoupling of the beta-adrenergic receptor system.

287 ated through signaling pathways identical to beta-adrenergic receptors, thus providing support that i

288 del the flow of spatial information from the beta-adrenergic receptor to MAPK1,2 through the cAMP/PKA

289 lting from impaired signal transduction from beta-adrenergic receptors to adenylate cyclase.

290 ry pathways and discovered that NA activates beta-adrenergic receptors to boost LTP maintenance in ar

291 cellular populations that express different beta-adrenergic receptors to induce beige adipogenesis.

292 aimed to examine whether the ability of the beta-adrenergic receptors to offset the transduction of

293 of the L-type current by stimulation of the beta-adrenergic receptor was unaffected in vivo and in c

294 iomas are reported to express high levels of beta adrenergic receptors, we examined the expression of

295 ion of PKA through G(s)-coupled dopamine and beta-adrenergic receptors, which regulate the late-phase

296 prediction that a complete antagonist of the beta-adrenergic receptor will likely block long-lasting

297 Blockade of beta-adrenergic receptors with atenolol abolished the pu

298 Stimulation of Galphas-coupled beta-adrenergic receptors with isoproterenol induced PKA

299 These results suggest that stimulation of beta-adrenergic receptors with isoproterenol leads to de

300 antly, activation of endogenous cAMP-coupled beta-adrenergic receptors with norepinephrine stimulated